Business Wire

LR-HEALTH-&-BEAUTY-SYSTE

6.1.2015 09:36:16 CET | Business Wire | Pressemeddelelse

Del
LR Health & Beauty Systems GmbH: More Quality for Your Life

This year LR Health & Beauty Systems GmbH celebrates its 30th anniversary. Since its foundation in 1985, the Ahlen-based company has become one of the world's leading suppliers of premium health and beauty products in direct sales. The original idea was to sell high-quality perfumes at affordable prices through external and independent sales partners. This laid the foundation for LR. Today, the comprehensive range offered by LR includes perfumes, dietary supplements as well as personal care and decorative cosmetics. LR is a dedicated expert for aloe vera and anti-ageing products, which make up two of the company's core segments. With an annual harvest of 4.2 tonnes of aloe vera, which corresponds to around 24 million leaves of the lily of the desert, LR is one of the world's largest manufacturers of aloe vera products. Over the last three decades, the company has not only continued to extend its product portfolio but also responded to social trends and changes through strategic realignment. The most recent example is the new customer online shop which was launched in Germany in 2014 and offers end consumers the possibility to order LR products 24/7.

More quality in many respects

LR's company motto is "More quality for your life." The slogan reflects a product-based commitment to performance and, at the same time, a fundamental component of LR's business model. Patrick Sostmann, Management Spokesman of LR, said: "With our high-quality products from the beauty and health sectors, we wish to contribute to making life more beautiful and even more worth living for everyone. In addition, our direct sales model gives people an opportunity to improve their standard of living." To date, more than 300,000 registered independent sales partners and customers worldwide have seized this opportunity. In their daily work for LR, they can count on the support and advice of more than 1,100 LR employees, more than 600 of which at the Ahlen headquarters. Here, the company has set up its research and production site of more than 80,000 sqm.

Sustainable growth through investments

Currently, LR has a market presence in around 30 countries and continues to focus on sustainable, international growth. This includes the consistent development of growth markets such as Russia and France as well as the creation of new market opportunities, for instance in Eastern Europe. In its German home market, LR aims to maintain and consolidate its leadership role. Growth and success are based on investments in high-quality products and co-operations with international stars such as Bruce Willis, Karolina Kurkova and Guido Maria Kretschmer. LR also attaches great importance to training and advanced training programs for its sales partners. "We want to facilitate the work of our sales partners to the greatest possible extent by supporting them with all resources available to us," said Patrick Sostmann. Therefore, a fair and transparent remuneration model are as natural for LR as is individual support of the sales partners by means of customized training programmes at the LR Academy, which was established especially for this purpose.

Responsible leadership

Stringent internal monitoring and independent lab service providers like SGS INSTITUT FRESENIUS and Dermatest guarantee product quality. On all levels, from research and development to production through to shipment, the company has committed itself to the conservation of resources and environmental protection. LR does not test its products on animals and invests in ecologically-friendly production processes and energy-saving logistics solutions. In order to remain a trendsetter in the industry, the company management is actively involved in leading associations of the individual industries.

Every parcel helps children in need

The motto "More quality for your life." is also reflected in LR's social commitment. In 2009, employees of the company founded the charitable association "LR Global Kids Fund" (LRGKF) which provides support for children in need. In order to be able to offer swift assistance, LRGKF has established co-operations with local organisations in the respective countries. The association supports the children’s “Lunch Club” restaurant in Ahlen/Germany, for instance. A part of the funds is raised through the 2.7 million parcels which are shipped to sales partners and customers every year. A fixed amount for every parcel goes to LRGKF. In addition, the association can already count on the support of a great number of LR sales partners.

LR Health & Beauty Systems GmbH

Under the motto "More quality for your life“, the LR Group with headquarters in Ahlen/Germany produces and markets more than 600 health and beauty products in around 30 countries. This includes body care and cosmetic products, perfumes and dietary supplements. In the fragrance segment, the company, which was founded in 1985, cooperates with celebrities such as Bruce Willis, Karolina Kurkova and Guido Maria Kretschmer. With more than 1,100 employees and around 300,000 registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. Since 2014, in Germany, LR products can be ordered 24/7 from the company's customer online shop. LR's strong market position is based above all on a high-quality product range and an attractive bonus and training plan which is unsurpassed in the industry. In 2009, LR employees established the LR Global Kids Fund which provides efficient support for deprived children and their families in many different countries around the world in cooperation with local institutions.

Contact:

LR Health & Beauty Systems GmbH
Almut Kellermeyer
Head of PR/Public Affairs
Telefon +49 (0) 2382 7060-106
Telefax +49 (0) 2382 7060-179
E-Mail: a.kellermeyer@LRworld.com
or
Vanessa Lange
PR-Manager
Telefon +49 (0) 2382 7060-107
Telefax +49 (0) 2382 7060-179
E-Mail: v.lange@LRworld.com
or
LRworld.com
facebook.com/LRworld
twitter.com/LRworld

Link:

Multimedia Gallery

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye